Online ISSN: 2515-8260

Keywords : Neopterin

Sepsis Markers at PICU and the Utility of Serum Neopterin

Osama GamalAbdElhamid, Samir Mohamed Zamzam, Amr Mogahed Abu Elnga, Nourhan Abdallah Saeed

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 3813-3823

Background:Septicemia is a potential clinical status which is a result of irresistible sickness or a
inflammatory process secondary to infection or injury. Clinical management of septicemia
requires brief research facility finding and plan of successful patient administration techniques that
might incorporate antimicrobial chemotherapy. Despite the fact that the accessible biomarkers of
septicemia, for example, CRP, procalcitonin has ended up being helpful, their disadvantages is
elevation in non-septic conditions like injury, surgery, and different conditions like systemic
inflammatory reaction disorder (SIRS), and insusceptible reaction amid septic conditions.
Considering the way that septicemia because of contamination is microbiologically affirmed just
in 30% of the cases, it is inescapable that there is requirement for different markers of septicemia.
Neopterin is one of biochemical markers of immune activity, which seems to be useful in
monitoring inflammatory diseases. Increased concentration of neopterin in serum is observed in
conditions with involvement of cell mediated immune response. Investigations on critically ill
patients on intensive care units evaluated neopterin levels as tool to discriminate patients with
systemic inflammatory response syndrome with and without infectious etiology. Neopterin levels
were found to have a specificity of 78% for discriminating infectious and noninfectious etiology of
critical illness

Biomarkers of Tuberculosis – A Review

Ritika sharma

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 4851-4867

According to recent World Health Organization reports, Tuberculosis is regarded to be the most severe disease caused by infection. There are significant drawbacks to the testing used for TB diagnosis and there is no accurate point-of-care (POC) diagnostic examination. New methods are required worldwide to controlling tuberculosis (TB). In general, new diagnostic methods and new biomarkers are necessary to assess both pathogenic and host main elements of an infection response. Biomarker-based or multiple marker biosignature-based tests, preferably conducted on blood or urine, for the identification of active TB may help achieve the target drug profiles recommended for point-of-care testing by the World Health Organization. Here I review The identified forms of biomarkers included antibodies, cytokines, metabolic markers, mycobacterial antigens and volatile organic compounds and the different biomarkers of tuberculosis, like,LAM ,IFN-g ,myolic acid ,antigen 85,different VOCs,Rv1681 protein,CFP-10,granzyme A